Cancer vaccine prevents deadly melanoma from returning or spreading in landmark trial
Merck and Moderna's mRNA cancer vaccine hit its Phase 3 trial endpoint, showing improved recurrence-free survival in melanoma patients after surgery.
Merck and Moderna's mRNA cancer vaccine hit its Phase 3 trial endpoint, showing improved recurrence-free survival in melanoma patients after surgery.
Read the full article on Fox News
Read Full Article →